drugset / Trial / NCT02616666
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
Phase 4
Completed
632 enrolled
University of Liverpool
AstraZeneca · collabClinical Practice Research Datalink · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Timeline
- Start
- 2016-08-25
- Primary completion
- 2025-12-12
- Completion
- 2025-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Metformin | Small molecule | — | — |
| Comparator | Nateglinide | Small molecule | — | — |
| Comparator | Pioglitazone | Small molecule | — | — |
| Comparator | Repaglinide | Small molecule | — | — |